1. Home
  2. GKOS vs NCLH Comparison

GKOS vs NCLH Comparison

Compare GKOS & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • NCLH
  • Stock Information
  • Founded
  • GKOS 1998
  • NCLH 1966
  • Country
  • GKOS United States
  • NCLH United States
  • Employees
  • GKOS N/A
  • NCLH N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • NCLH Marine Transportation
  • Sector
  • GKOS Health Care
  • NCLH Consumer Discretionary
  • Exchange
  • GKOS Nasdaq
  • NCLH Nasdaq
  • Market Cap
  • GKOS 8.4B
  • NCLH 9.3B
  • IPO Year
  • GKOS 2015
  • NCLH 2013
  • Fundamental
  • Price
  • GKOS $102.04
  • NCLH $19.14
  • Analyst Decision
  • GKOS Strong Buy
  • NCLH Buy
  • Analyst Count
  • GKOS 13
  • NCLH 17
  • Target Price
  • GKOS $161.54
  • NCLH $29.00
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • NCLH 16.1M
  • Earning Date
  • GKOS 04-30-2025
  • NCLH 04-30-2025
  • Dividend Yield
  • GKOS N/A
  • NCLH N/A
  • EPS Growth
  • GKOS N/A
  • NCLH 384.69
  • EPS
  • GKOS N/A
  • NCLH 1.89
  • Revenue
  • GKOS $383,481,000.00
  • NCLH $9,479,651,000.00
  • Revenue This Year
  • GKOS $27.84
  • NCLH $9.77
  • Revenue Next Year
  • GKOS $27.99
  • NCLH $10.43
  • P/E Ratio
  • GKOS N/A
  • NCLH $10.13
  • Revenue Growth
  • GKOS 21.85
  • NCLH 10.87
  • 52 Week Low
  • GKOS $88.16
  • NCLH $14.69
  • 52 Week High
  • GKOS $163.71
  • NCLH $29.29
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.88
  • NCLH 34.92
  • Support Level
  • GKOS $98.03
  • NCLH $19.25
  • Resistance Level
  • GKOS $108.62
  • NCLH $20.88
  • Average True Range (ATR)
  • GKOS 3.96
  • NCLH 0.83
  • MACD
  • GKOS 1.87
  • NCLH 0.23
  • Stochastic Oscillator
  • GKOS 47.86
  • NCLH 45.28

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

About NCLH Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.

Share on Social Networks: